{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:39:53Z","timestamp":1720449593523},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.trecan.2016.02.007","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T13:27:24Z","timestamp":1458221244000},"page":"163-165","source":"Crossref","is-referenced-by-count":6,"title":["Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis"],"prefix":"10.1016","volume":"2","author":[{"given":"Miles D.","family":"Houslay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2016.02.007_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2009.09.007","article-title":"Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown","volume":"35","author":"Houslay","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.trecan.2016.02.007_bib0060","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.3390\/ijms14048025","article-title":"Biophysical techniques for detection of cAMP and cGMP in living cells","volume":"14","author":"Sprenger","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2016.02.007_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.02.007_bib0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.trecan.2016.02.007_bib0075","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2015.6604","article-title":"Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma","volume":"313","author":"Loeb","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2016.02.007_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2016.02.028","article-title":"Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth","author":"Dhayade","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2016.02.007_bib0085","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/modpathol.2013.228","article-title":"A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value","volume":"27","author":"Wouters","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.trecan.2016.02.007_bib0090","doi-asserted-by":"crossref","first-page":"E924","DOI":"10.1073\/pnas.1106351108","article-title":"Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF","volume":"108","author":"Feige","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.trecan.2016.02.007_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1755-148X.2011.00849.x","article-title":"Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor","volume":"24","author":"Boyle","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.trecan.2016.02.007_bib0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580331600039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580331600039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T04:21:22Z","timestamp":1536898882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240580331600039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S240580331600039X"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2016.02.007","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}